Abstract:Alzheimer's Disease (AD) is a devastating neurodegenerative disorder without cure. Lack of the understanding of early molecular mechanisms hinders the development of efficient therapeutics. We have previously demonstrated that alterations in mitochondrial dynamics precede the onset of memory phenotype and the development of amyloid plaques in three transgenic animal models of familial Alzheimer's Disease (FAD). Here we provide evidence that treatment with CP2, a member of a family of tricyclic pyrone compounds, restores axonal trafficking in vivo, and averts cognitive and motor deficit in FAD (APP, PS1 and APP/PS1) mice. Changes in mitochondrial dynamics and function in vivo and in vitro were evaluated using real-time imaging of mitochondrial motility; mitochondrial respiration and the rate of glycolysis were detected using a XF24 Seahorse Extracellular Flux Analyzer; evaluation of the activity of OXFOS Complexes I-V was done using enzymatic reactions; and metabolic changes associated with CP2 treatment were done using LC- and GC-MS-based metabolomics. Behavior and memory functions in treated and untreated animals were detected with a battery of well established tests including novel object recognition test, rotarod, hanging bar, Y-maze test, and activity in a cage. CP2 did not cause adverse side effects and did not affect animal breeding. CP2-treated animals maintained normal weight; they also outperform untreated FAD mice and age-and gender-matched non-transgenic littermates in a battery of tests. Cognitive protection was achieved within 2 months after treatment of presymptomatic animals. Investigation of the molecular mechanism revealed that CP2 treatment restores mitochondrial dynamics in neurons in vivo and in vitro. Alleviation of the motor and memory phenotype was accompanied by only partial reduction in amyloid burden. Moreover, we detected an increase in synaptophysin levels in the brain of CP2-treated APP/PS1 mice compared to untreated animals, which correlated with an improvement in cognitive function. Our findings, for the first time, demonstrated that restoration of mitochondrial trafficking protects against cognitive dysfunction in AD. Our data poise CP2 as a promising therapeutic compound validating mitochondrial motility as an early therapeutic target for AD.

A novel PDHK inhibitor restored cognitive dysfunction and limited neurodegeneration without affecting amyloid pathology in 5xFAD mouse, a model of Alzheimer's disease

Genetic Inhibition of PDK1 Robustly Reduces Plaque Deposition and Ameliorates Gliosis in the 5×FAD Mouse Model of Alzheimer's Disease

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

The Prodrug of 7,8-Dihydroxyflavone Development and Therapeutic Efficacy for Treating Alzheimer's Disease.

A Novel Peroxidase Mimics And Ameliorates Alzheimer'S Disease-Related Pathology And Cognitive Decline In Mice

A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease

Modulation of Mitochondrial Complex I Activity Averts Cognitive Decline in Multiple Animal Models of Familial Alzheimer's Disease

Searching For Disease Modifiers-Pkc Activation And Hdac Inhibition-A Dual Drug Approach To Alzheimer'S Disease That Decreases A Beta Production While Blocking Oxidative Stress

RESTORATION OF AXONAL TRAFFICKING OF MITOCHONDRIA AVERTS COGNITIVE DECLINE IN MOUSE MODELS OF FAMILIAL ALZHEIMER'S DISEASE

Effect of cx-DHED on Abnormal Glucose Transporter Expression Induced by AD Pathologies in the 5xFAD Mouse Model

Emx1-Cre-mediated Inactivation of PDK1 Prevents Plaque Deposition in an Alzheimer’s Disease-Like Mouse Model

Discovery of a Novel Chemotype As DYRK1A Inhibitors Against Alzheimer’s Disease: Computational Modeling and Biological Evaluation

Partial inhibition of mitochondrial complex I ameliorates Alzheimer’s disease pathology and cognition in APP/PS1 female mice

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease <i>in vitro</i> and <i>in vivo</i>

Partial inhibition of mitochondrial complex I attenuates neurodegeneration and restores energy homeostasis and synaptic function in a symptomatic Alzheimer’s mouse model

Pathological BBB Crossing Melanin-Like Nanoparticles as Metal-Ion Chelators and Neuroinflammation Regulators against Alzheimer’s Disease

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo

A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies

Direct Inhibition of Keap1-Nrf2 Protein-Protein Interaction As a Potential Therapeutic Strategy for Alzheimer's Disease.

DRD1 agonist A-68930 improves mitochondrial dysfunction and cognitive deficits in a streptozotocin-induced mouse model

The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model